Literature DB >> 27995576

Serine residues at positions 162 and 166 of the rabies virus phosphoprotein are critical for the induction of oxidative stress in rabies virus infection.

Wafa Kammouni1, Heidi Wood2,3, Alan C Jackson4,5,6.   

Abstract

Our previous work in a mouse model of experimental rabies showed neuronal process (dendrites and axons) degeneration in association with severe clinical disease. Cultured adult rodent dorsal root ganglion (DRG) neurons infected with the challenge virus standard-11 (CVS) strain of rabies virus (RABV) showed axonal swellings and reduced axonal growth with evidence of oxidative stress. We have shown that CVS infection alters a variety of mitochondrial parameters and increases mitochondrial complex I activity and reactive oxygen species (ROS) production. Expression of a peptide from amino acid 139-172 of the CVS phosphoprotein (P) increased complex I activity and ROS generation similar to expression of the entire P. Site-directed mutational analyses illustrated the importance of the 145-151 and 157-169 regions of P and that serine residues at 162 and 166 are important single amino acid sites. Two CVS recombinant viruses with serine to alanine mutations at positions 162 (A162r) and 166 (A166r) did not increase complex I activity or ROS generation and also did not induce axonal swellings or inhibit axonal growth in DRG neurons. RABV infection is a mitochondrial disorder initiated by interaction of the RABV P and complex I; S162 and S166 are critical sites in the P for this interaction. The resulting mitochondrial dysfunction produces oxidative stress in neurons causing acute degenerative changes affecting neuronal processes resulting in a severe and fatal clinical disease. This information will be important for the future development of novel therapies for rabies.

Entities:  

Keywords:  Oxidative stress; Pathogenesis; Rabies; Rabies virus; Reactive oxygen species

Mesh:

Substances:

Year:  2016        PMID: 27995576     DOI: 10.1007/s13365-016-0506-8

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  26 in total

1.  Phosphorylation within the amino-terminal acidic domain I of the phosphoprotein of vesicular stomatitis virus is required for transcription but not for replication.

Authors:  A K Pattnaik; L Hwang; T Li; N Englund; M Mathur; T Das; A K Banerjee
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

Review 2.  Cytoprotection by the modulation of mitochondrial electron transport chain: the emerging role of mitochondrial STAT3.

Authors:  Karol Szczepanek; Qun Chen; Andrew C Larner; Edward J Lesnefsky
Journal:  Mitochondrion       Date:  2011-09-10       Impact factor: 4.160

Review 3.  Genetic animal models of Parkinson's disease.

Authors:  Ted M Dawson; Han Seok Ko; Valina L Dawson
Journal:  Neuron       Date:  2010-06-10       Impact factor: 17.173

4.  Phosphorylation in protein-protein binding: effect on stability and function.

Authors:  Hafumi Nishi; Kosuke Hashimoto; Anna R Panchenko
Journal:  Structure       Date:  2011-12-07       Impact factor: 5.006

5.  Human parainfluenza virus type 3 phosphoprotein: identification of serine 333 as the major site for PKC zeta phosphorylation.

Authors:  C C Huntley; B P De; N R Murray; A P Fields; A K Banerjee
Journal:  Virology       Date:  1995-08-20       Impact factor: 3.616

6.  Structural abnormalities in neurons are sufficient to explain the clinical disease and fatal outcome of experimental rabies in yellow fluorescent protein-expressing transgenic mice.

Authors:  Courtney A Scott; John P Rossiter; R David Andrew; Alan C Jackson
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

7.  Rabies virus glycoprotein is an important determinant for the induction of innate immune responses and the pathogenic mechanisms.

Authors:  Guoqing Zhang; Hualei Wang; Fazal Mahmood; Zhen F Fu
Journal:  Vet Microbiol       Date:  2012-11-29       Impact factor: 3.293

8.  Mitochondrial dysfunction in lyssavirus-induced apoptosis.

Authors:  Alireza Gholami; Raïd Kassis; Eléonore Real; Olivier Delmas; Stéphanie Guadagnini; Florence Larrous; Dorothée Obach; Marie-Christine Prevost; Yves Jacob; Hervé Bourhy
Journal:  J Virol       Date:  2008-03-05       Impact factor: 5.103

9.  A novel neuroprotective therapy for Parkinson's disease using a viral noncoding RNA that protects mitochondrial complex I activity.

Authors:  Wei-Li Kuan; Emma Poole; Michael Fletcher; Sharon Karniely; Pam Tyers; Mark Wills; Roger A Barker; John H Sinclair
Journal:  J Exp Med       Date:  2011-12-19       Impact factor: 14.307

10.  Generation of recombinant rabies Virus CVS-11 expressing eGFP applied to the rapid virus neutralization test.

Authors:  Xianghong Xue; Xuexing Zheng; Hongru Liang; Na Feng; Yongkun Zhao; Yuwei Gao; Hualei Wang; Songtao Yang; Xianzhu Xia
Journal:  Viruses       Date:  2014-04-04       Impact factor: 5.048

View more
  4 in total

1.  Lyssavirus phosphoproteins increase mitochondrial complex I activity and levels of reactive oxygen species.

Authors:  Wafa Kammouni; Heidi Wood; Alan C Jackson
Journal:  J Neurovirol       Date:  2017-07-05       Impact factor: 2.643

2.  Comprehensive Analysis of Protein Acetylation and Glucose Metabolism in Mouse Brains Infected with Rabies Virus.

Authors:  Jie Pei; Yueming Yuan; Dayong Tian; Fei Huang; Chengguang Zhang; Caiqian Wang; Ming Zhou; Huanchun Chen; Zhenfang Fu; Ling Zhao
Journal:  J Virol       Date:  2021-12-08       Impact factor: 6.549

3.  Optimization of Inhibitory Peptides Targeting Phosphoprotein of Rabies Virus.

Authors:  Yongzhong Lu; Linyue Cheng; Jie Liu
Journal:  Int J Pept Res Ther       Date:  2019-08-13       Impact factor: 1.931

4.  A One Medicine Mission for an Effective Rabies Therapy.

Authors:  Darryn L Knobel; Alan C Jackson; John Bingham; Hildegund C J Ertl; Andrew D Gibson; Daniela Hughes; Kenneth Joubert; Reeta S Mani; Bert J Mohr; Susan M Moore; Hugh Rivett-Carnac; Noël Tordo; James W Yeates; Anthony B Zambelli; Charles E Rupprecht
Journal:  Front Vet Sci       Date:  2022-03-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.